Skip to main content

Table 1 Patient demographics and characteristics

From: Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores

  All patientsa (N = 21,991) No chemotherapyb (N = 17,345) chemotherapyb (N = 4646)  
Characteristic n % n % n % p valuec
Facility type        < 0.001
 Community cancer program 1914 8.7 1504 8.7 410 8.8  
 Comprehensive community cancer program 10,435 47.5 8379 48.3 2056 44.3  
 Academic/research program 7172 32.6 5666 32.7 1506 32.4  
 Other 2470 11.2 1796 10.4 674 14.5  
Age category (years)        < 0.001
 < 40 747 3.4 390 2.3 357 7.7  
 40–49 4735 21.5 3287 19.0 1448 31.2  
 50–59 7014 31.9 5380 31.0 1634 35.2  
 60–69 6823 31.0 5810 33.5 1013 21.8  
 70–79 2469 11.2 2288 13.2 181 3.9  
 80+ 203 0.9 190 1.1 13 0.3  
Race/ethnicity        0.004
 Non-Hispanic White 17,628 80.2 13,982 80.6 3646 78.5  
 Non-Hispanic Black 1535 7.0 1189 6.9 346 7.5  
 Hispanic 898 4.1 685 4.0 213 4.6  
 Non-Hispanic Asian/Pacific 761 3.5 569 3.3 192 4.1  
 Other 1169 5.3 920 5.3 249 5.4  
Primary payer        < 0.001
 Not insured 341 1.6 248 1.4 93 2.0  
 Private insurance 14,567 66.2 10,994 63.4 3573 76.9  
 Medicaid 1172 5.3 881 5.1 291 6.3  
 Medicare 5479 24.9 4880 28.1 599 12.9  
 Other 432 2.0 342 2.0 90 1.9  
Urban/rural        0.62
 Metro counties 18,447 83.9 14,531 83.8 3916 84.3  
 Urban counties 2657 12.1 2120 12.2 537 11.6  
 Rural counties 354 1.6 275 1.6 79 1.7  
 Unknown 533 2.4 419 2.4 114 2.5  
Charlson–Deyo score        < 0.001
 0 19,070 86.7 14,980 86.4 4090 88.0  
 1 2540 11.6 2035 11.7 505 10.9  
 ≥ 2 381 1.7 330 1.9 51 1.1  
Grade        < 0.001
 Well differentiated, differentiated, NOS 5723 26.0 4971 28.7 752 16.2  
 Moderately differentiated, moderately well differentiated, intermediate differentiation 12,305 56.0 9709 56.0 2596 55.9  
 Poorly differentiated 2780 12.6 1751 10.1 1029 22.2  
 Undifferentiated, anaplastic 13 0.1 8 0.1 5 0.1  
 Cell type not determined, not stated or not applicable, unknown primaries, high-grade dysplasia 1170 5.3 906 5.2 264 5.7  
AJCC pathologic stage        < 0.001
 T1C 15,766 71.7 12,827 74.0 2939 63.3  
 T2 6225 28.3 4518 26.1 1707 36.7  
Lymphovascular invasion        < 0.001
 Not present 17,155 78.0 13,795 79.5 3360 72.3  
 Present 2199 10.0 1507 8.7 692 14.9  
 Not applicable 14 0.1 10 0.1 4 0.1  
 Unknown 2623 11.9 2033 11.7 590 12.7  
Type of surgery        < 0.001
 Breast conservation 15,468 70.3 12,426 71.6 3042 65.5  
 Mastectomy 6521 29.7 4919 28.4 1602 34.5  
 Unknown 2 0.01 0 0.0 2 0.04  
Margin status        0.01
 Negative 21,189 96.4 16,745 96.5 4444 95.7  
 Positive 725 3.3 544 3.1 181 3.9  
 Unknown 77 0.4 56 0.3 21 0.5  
Radiation therapy        < 0.001
 None 6557 29.8 5032 29.0 1525 32.8  
Beam radiation 14,116 64.2 11,183 64.5 2933 63.1  
 Other/unknown 1318 6.0 1130 6.5 188 4.1  
Radiation treatment volume        < 0.001
 No radiation treatment 6556 29.8 5031 29.0 1525 32.8  
 Breast or chest wall 14,829 67.4 11,875 68.5 2954 63.6  
 Breast/lymph nodes or chest wall/lymph nodes 470 2.1 350 2.0 120 2.6  
 Other 53 0.2 36 0.2 17 0.4  
 Unknown 83 0.4 53 0.3 30 0.7  
  1. AJCC American Joint Committee on Cancer, NOS not otherwise specified
  2. aCharacteristics for all patients who met inclusion criteria for this study
  3. bComparison of characteristics for the patients who did not receive chemotherapy to the patients who did receive chemotherapy
  4. cDifferences between these two populations on univariate analysis
\